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Abstract
Background: Malarial anaemia is characterized by destruction of malaria infected red blood cells and suppression
of erythropoiesis. Interleukin 12 (IL12) significantly boosts erythropoietic responses in murine models of malarial
anaemia and decreased IL12 levels are associated with severe malarial anaemia (SMA) in children. Based on the
biological relevance of IL12 in malaria anaemia, the relationship between genetic polymorphisms of IL12 and its
receptors and SMA was examined.
Methods: Fifty-five tagging single nucleotide polymorphisms covering genes encoding two IL12 subunits, IL12A
and IL12B, and its receptors, IL12RB1 and IL12RB2, were examined in a cohort of 913 children residing in Asembo
Bay region of western Kenya.
Results: An increasing copy number of minor variant (C) in IL12A (rs2243140) was significantly associated with a
decreased risk of SMA (P = 0.006; risk ratio, 0.52 for carrying one copy of allele C and 0.28 for two copies).
Individuals possessing two copies of a rare variant (C) in IL12RB1 (rs429774) also appeared to be strongly protective
against SMA (P = 0.00005; risk ratio, 0.18). In addition, children homozygous for another rare allele (T) in IL12A
(rs22431348) were associated with reduced risk of severe anaemia (SA) (P = 0.004; risk ratio, 0.69) and of severe
anaemia with any parasitaemia (SAP) (P = 0.004; risk ratio, 0.66). In contrast, AG genotype for another variant in
IL12RB1 (rs383483) was associated with susceptibility to high-density parasitaemia (HDP) (P = 0.003; risk ratio, 1.21).
Conclusions: This study has shown strong associations between polymorphisms in the genes of IL12A and IL12RB1
and protection from SMA in Kenyan children, suggesting that human genetic variants of IL12 related genes may
significantly contribute to the development of anaemia in malaria patients.
Background
Malaria continues to be a major global public health
burden, causing 250 million clinical cases and nearly
one million deaths annually, of which 85% are children
under the age of five. About 86% of malaria cases and
over 91% of malaria deaths worldwide occur in sub-
Saharan Africa [1,2]. Cerebral malaria and severe malar-
ial anaemia (SMA) are two major syndromes causing
malaria-related mortality in children. The pattern of
these two severe forms varies depending on the intensity
of transmission: cerebral malaria is more common in
older children in areas with lower intensity of transmis-
sion, whereas SMA is often seen in children below two
years of age in areas with intense transmission [3], such
as western Kenya, where Plasmodium falciparum infec-
tion is most common [4].
The human host response to P. falciparum can vary.
While some infected individuals die of severe malaria,
others survive, and still others are infected without
becoming severely ill. It has been estimated that host
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genetic factors account for ~25% of the risk of severe
malaria [5]. Malaria has exerted significant pressure on
the human genome to select for mutations conferring
refractoriness to malaria [6]. This is illustrated by several
well studied mutations that protect against different
forms of malaria, including sickle cell allele, Duffy muta-
tions, and alpha thalassaemia [7]. An increasing amount
of published information has documented a number of
genetic associations with malaria susceptibility. The
majority of these concern genes coding for molecules
involved in physiology of red blood cells or in the host
immune response[8]. It is only beginning to understand
the human genetic factors that determine resistance to
malaria.
Malarial anaemia is characterized by destruction of
malaria infected red blood cells and suppression of ery-
thropoiesis [9-11]. Although the mechanisms of erythro-
poietic suppression associated with pathogenesis of
malarial anaemia are poorly understood, studies in mur-
ine models of malarial anaemia have demonstrated that
interleukin 12 (IL12) significantly boosts erythropoietic
responses by enhancement of erythroid progenitor
expansion and immune regulation [12-15], and adminis-
tration of IL12 corrects malarial anaemia [12,16,17].
Moreover, several immuno-epidemiological studies con-
ducted in malaria endemic areas have shown that
decreased IL12 levels are associated with an increased
risk of SMA in children [18-20]. Taken together, these
findings suggest that reductions of IL12 in malaria infec-
tion could lead to SMA by suppression of erythropoiesis.
IL12 is a pro-inflammatory cytokine with a pleiotropic
effect as a potent immunoregulatory molecule and hae-
matopoietic growth factor in infections with Plasmo-
dium parasites [14]. It is a disulfide-linked heterodimer
composed of a 35 kD subunit encoded by IL12A and 40
kD subunit encoded by IL12B and exerts its biological
effects through binding to heterodimeric receptors
encoded by IL12RB1 and IL12RB2. The region contain-
ing IL12B, chromosome 5q31-q33, is linked to P. falci-
parum parasite density in linkage analysis studies
[21,22]. A functional promoter variant in IL12B, IL12B-
pro (rs17860508) is associated with protection against
cerebral malaria in children [23]. These results suggest
that IL12 is an important candidate gene in host resis-
tance to severe malaria.
Given the biological relevance of IL12 in malarial
anaemia and the genetic linkage of IL12B in malaria
infection and severe disease (cerebral malaria), the
potential associations of differences in genes encoding
two human IL12 subunits, IL12A and IL12B, and recep-
tors, IL12RB1 and IL12RB2, in the risk of developing
SMA has been investigated by retrospectively genotyp-
ing samples collected from an infant cohort study,
Asembo Bay Cohort Project (ABCP) [24]. This study
presents findings of the first significant genetic associa-
tion within the IL12A and IL12RB1, which are asso-
ciated with protection against SMA among young
children in western Kenya.
Methods
Participants
This study was part of Asembo Bay Cohort Project, an
immuno-epidemiologic birth cohort project conducted
from June 1992 through September 1996. Characteristics
of this study have been detailed elsewhere [24]. Briefly,
the study was carried out in a rural area of western
Kenya where more than 95% of the residents belong to
the Luo ethnic group, malaria transmission is holoen-
demic, and severe anaemia is a major cause of malaria-
related mortality in children less than two years of age.
Pregnant women were enrolled in their second or last
trimester; their newborn babies were enrolled soon after
birth and followed up to three to five years of life. Vil-
lage monitors visited each mother-child pair every two
weeks for clinical observation. At monthly intervals (and
between intervals when children were sick), blood sam-
ples were obtained for measurement of parasitaemia and
haemoglobin concentrations. Resulting data, along with
time to first documented malaria infection, parasite den-
sity of first infection, and cumulative treatment with sul-
phadoxine/pyrimethamine were available as part of
routine data collection. For the current genetic associa-
tion study, longitudinal clinical information up to two-
year follow-up from the time of enrollment was used
since this age group accounted for most of the observed
malarial anaemia [25].
Inclusion criteria for children in this genetic associa-
tion study included having at least 1 monthly follow-up
visit up to two years of age and availability of sample.
Mean numbers of visits including both monthly follow-
ups and sick visits during first two years of life were
19.8 (SD = 11.5) for the included children. Additionally,
for genetic association analyses, it is important that all
participants are genetically unrelated individuals. There-
fore, only children from singleton births or one of the
twins were included in the study. If more than one
family member (siblings) was eligible based on the
above criteria, only the first child in birth order was
included in the study.
Informed written consent was obtained from parents/
guardians of all study participants. This study was
approved by the Institutional Review Board of the
Kenya Medical Research Institute and Centers for Dis-
ease Control and Prevention.
Phenotypic definitions
A classification scheme [26], based on previous epide-
miological analysis of the same cohort [25], was used in
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this study. SMA was defined as a haemoglobin concen-
tration of less than 6 g/dL and the presence of P. falci-
parum greater than 10,000/μl. Three other
subphenotypes used in this study were: severe anaemia
(SA) (Hb < 6 g/dL), high-density parasitaemia (HDP) (>
10,000 P. falciparum parasites/μl), and severe anaemia
with any level of parasitaemia (SAP) (Hb < 6 g/dL with
any detectable P. falciparum parasitaemia). All data
points collected monthly and at sick visits for two years
in children were used and the clinical phenotypes are
presented as episode crude incidence/1,000 person-
months.
Single nucleotide polymorphism (SNP) selection
For tagging SNP (tagSNP) selection, LDSelect software
at default settings (r2 > 0.65) was used to select tagSNPs
from all common variation within four IL12 related
genes from a public database of SeattleSNPs [27]. LDSe-
lect uses an efficient selection algorithm to select tag-
ging SNPs based on linkage disequilibrium (LD) statistic
r2 and does not require direct haplotype inference [28].
At each round of selection, the binning algorithm iden-
tifies single SNP, which exceeds threshold r2 with the
maximum number of other SNPs, and sets this group of
SNPs as a bin. Then each SNP within the bin is ana-
lysed to determine whether it exceeds the threshold r2
with all other SNPs in the bin. All SNPs in a bin that
meet this criterion are designated as tagSNPs. Only one
tagSNP needs to be typed per bin. Binning criteria for
tagSNP selection used in this study were minor allele
frequency (MAF) cut-off of 10% and an r2 threshold of
0.65. LD varies across different populations [29,30];
therefore, only genotype data for the African-American
samples present in the database was used, as this popu-
lation is most similar to the samples in this study from
western Kenya. Fifty five tagSNPs, 7 in IL12 A, 10 in
IL12B, 22 in IL12RB1, and 16 in IL12RB2 were selected.
Many more SNPs were needed for IL12RB1 gene than
for other genes tested due to its larger size and the
genetic diversity.
Genotyping
DNA was extracted from frozen blood pellets using a
QiaAMP DNA purification kit (Qiagen). For each sam-
ple, 10 ng DNA was spotted into 384-well plates
(ABgene), dried and frozen until just before use in geno-
typing assays. SNPs were genotyped using the MassAR-
RAY® iPLEX assay (Sequenom)[31]. Multiplex PCR
primers (up to 29-plex) were designed in a region of
approximately 100 base pairs around the SNP of interest
and an extension primer was designed immediately adja-
cent to the SNP using MassArray Assay Design software
(version 3.1). The single base primer extension step was
performed using a standardized cycling programme.
Primer extension products were dispensed on 384-well
SpectroChip®s that were automatically read by a Com-
pact™ MALDI-TOF mass spectrometer (Sequenom).
Data analysis was performed on MassArray Typer soft-
ware (version 3.4).
Data quality control and statistical analysis
Genotypes were individually examined via a detailed
quality control process involving duplicate calling of
genotypes, control samples, evaluation of missing calls,
and Hardy–Weinberg Equilibrium (HWE) testing. The
iPLEX genotype clusters were manually checked. Only
SNPs with > 90% calling rate and MAF > 2% were
including in the final analysis. Each SNP was analysed
using univariate methods and then multivariate Poisson
regression analysis to ascertain the association between
genotypes and malaria-associated morbidity. Generalized
estimating equations and an independent working corre-
lation structure to adjust for correlation between multi-
ple visits from the same individual were used. In the
multivariate Poisson regression, SNPs were indepen-
dently evaluated as covariates using one of four genetic
models: dominant ((AA + Aa) vs aa), recessive (AA vs
(Aa + aa)), additive (aa vs Aa vs AA, which treat the
marker as a continuous variable), and heterozygous
advantage (Aa vs (AA + aa)) with three levels based on
the most common allele frequency. Here, “A” refers the
common allele. The results of the Poisson regression
were reported as rate ratios (or risk ratios, RR). Multi-
variate models were adjusted for confounders, sickle cell
type and treatment with anti-malarial drugs since these
two factors were significantly associated with all four
clinical phenotypes in univariate analysis (Table 1). Data
was analysed using SAS software package (version 9.1).
Bonferroni adjusted critical alpha level of 0.007 for
IL12A, 0.006 for IL12B, 0.005 for IL12RB1, and 0.004
for IL12RB2 were used. Haploview was used to obtain
values for LD and perform haplotype block analysis of
SNPs in the same gene [32,33]. D prime values (D’)
were calculated as statistical values for pairwise LD ana-
lysis between SNPs.
Results
Characteristics of study participants
Among 1,459 children enrolled in ABCP, 913 meeting
inclusion criteria (62.6%) were selected for genotyping.
In this study, incidence of at least one SMA episode in
the same individual was 16.5% during the first two years
of life, 44.5% for SA, 79.5% for HDP, and 40.0% for SAP.
Only sickle cell type and history of anti-malarial use
were significantly associated with all four clinical pheno-
types of interest in the unadjusted analysis (Table 1).
These two covariates were therefore included in the final
model of multivariate Poisson regression analysis. Other
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covariates, such as bed net use, amount of rain in pre-
vious 120 days, parasitaemia in the mothers at the time
of delivery, and low birth weight (< 2500 g) or pre-term
birth (< 37 weeks gestation), were not significantly asso-
ciated with all four clinical phenotypes although parasi-
taemia in mother was associated with SA only and
low birth weight and pre-term birth were associated
with HDP.
Genotyping
Fifty-five tagSNPs were selected for genotyping from
genes encoding IL12 A, IL12 B, IL12RB1, and IL12RB2.
Eight SNPs were not polymorphic in this population,
and nine did not perform sufficiently in the multiplexed
assay or pass quality control process (Table 2). Thirty-
eight SNPs were included in the final analysis (Addi-
tional file 1).
Association of gene polymorphisms in IL12 and its
receptor with clinical phenotypes
This study identified an association with SMA for two
SNPs, rs2243140 of IL12A and rs429774 of IL12RB1,
both of which were associated with protection from
SMA (Table 3). Specifically, for rs2243140 of IL12A, an
increasing copy number of minor allele C (TT vs TC vs
CC) was significantly associated with a reduced risk of
SMA (P = 0.006). For rs429774 of IL12RB1, individuals
possessing two copies of minor variant C appeared to be
associated with a reduced risk of SMA (P = 5 × 10-5).
The risk for developing SMA over time based on risk
ratios calculated from multivariate Poisson regression
was reduced by 82% (95% CI: 31%-95%) if carrying two
copies of minor allele (CC) of rs429774 compared with
those carrying one or no copies of the C allele. No sta-
tistically significant interaction between these two SNPs
Table 1 Characteristics of 913 infants selected from Asembo Bay Cohort Project
Subjects, no. of any incidence (%)a
Total SAb P HDPc P SAPd P SMAe Pf
Sex
Male 441 213 (48) .03 357 (81) .33 192 (44) .03 77 (18) .33
Female 472 194 (41) 370 (78) 172 (36) 71 (15)
Sickle cell type
AS 147 51 (35) .01 112 (77) .02 46 (31) .03 13 (9) .008
AA 656 316 (48) 547 (83) 280 (43) 122 (17)
SS 25 13 (52) 17 (68) 12 (48) 2 (8)
Anti-malarial use
Yes 786 371 (47) < .0001 661 (84) < .0001 331 (42) .0006 137 (17) .01
No 127 36 (28) 66 (52) 33 (26) 11 (9)
Placental blood parasitaemia
Yes 210 84 (40) .05 161 (77) .11 76 (36) .09 35 (17) .93
No 481 232 (48) 394 (82) 207 (43) 79 (16)
Maternal peripheral parasitaemia
Yes 296 121 (41) 0.1 230 (78) .25 109 (37) .17 57 (19) .11
No 598 279 (47) 484 (81) 249 (42) 90 (15)
Birth weight < 2500 g or gestation age < 37 weeks
Yes 82 35 (43) .58 59 (72) .03 31 (38) .54 15 (18) .58
No 636 292 (46) 522 (82) 263 (41) 101 (16)
Low birth weight (< 2500 g)
Yes 71 29 (41) .41 51 (72) .05 25 (35) .31 13 (18) .61
No 651 299 (46) 532 (82) 270 (41) 104 (89)
Pre-term birth (< 37 weeks gestation)
Yes 29 11 (38) .44 18 (62) .01 10 (35) .51 3 (10) .37
No 846 382 (45) 685 (81) 343 (41) 141 (17)
NOTE
a Any incidence: at least once; displayed are frequency counts (percentage).
b SA: Severe anaemia (Hb < 6 g/dL).
c HDP: High density parasitaemia (> 10,000 P. falciparum parasites/μl).
d SAP: Severe anaemia with any density parasitaemia (Hb < 6 g/dL with any detectable P. falciparum parasitaemia).
e SMA: Severe malaria anaemia Hb < 6 g/d Land > 10,000 P. falciparum parasites/μl)
f Chi-square p-values.
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Table 2 List of SNPs of IL12A, IL12B, IL12RB1 and IL12BR2 tested in this study
SNP rs# Gene(s) Alleles SNP position MAF* Role AA change
rs2243113 IL12A A/G chr3:161188557 0.08 Promoter -
rs582054 IL12A T/A chr3:161192695 0.21 Intron -
rs583911 IL12A A/G chr3:161193084 0.11 Intron -
rs2243128 IL12A G/A chr3:161193205 0.17 Intron -
rs2243138 IL12A A/T chr3:161197044 0.47 Downstream -
rs2243140 IL12A T/C chr3:161197241 0.11 Downstream -
rs2243143 IL12A A/G chr3:161197496 0.45 Downstream -
rs3212227 IL12B A/C chr5:158675537 0.39 3’ UTR -
rs3213119 IL12B C/A chr5:158676366 0.00 Coding exon 298 V/F
rs2195940 IL12B C/T chr5:158676930 0.25 Intron -
rs3213103 IL12B G/A chr5:158679014 0.07 Intron -
rs3213099 IL12B C/G chr5:158680114 0.02 Intron (boundary) -
rs919766 IL12B A/C chr5:158680142 0.28 Intron (boundary) -
rs2853694 IL12B T/G chr5:158681666 0.17 Intron -
rs3213096 IL12B C/T chr5:158682907 0.00 Coding exon 33 V/I
rs2569253 IL12B T/C chr5:158683571 0.17 Intron -
rs2569254 IL12B C/T chr5:158683827 0.06 Intron -
rs3746190 IL12RB1 G/A chr19:18031384 0.07 3’ UTR -
rs383483 IL12RB1 A/G chr19:18032886 0.44 Intron (boundary) -
rs438421 IL12RB1 C/T chr19:18037086 0.30 Intron -
rs2045386 IL12RB1 G/A chr19:18043266 0.28 Intron -
rs447171 IL12RB1 C/T chr19:18045647 0.27 Intron -
rs11575934 IL12RB1 T/C chr19:18047618 0.14 Coding exon 214 Q/R
rs429774 IL12RB1 T/C chr19:18047752 0.24 Intron (boundary) -
rs17882031 IL12RB1 C/T chr19:18048349 0.00 Intron -
rs11575926 IL12RB1 C/T chr19:18049408 0.00 Coding exon 156 R/H
rs11575925 IL12RB1 G/C chr19:18053977 0.00 Coding exon 74 S/R
rs897751 IL12RB1 A/G chr19:18054349 0.30 Intron -
rs439409 IL12RB1 G/A chr19:18054613 0.32 Intron -
rs17884651 IL12RB1 C/A chr19:18058626 0.00 Coding exon 3 P/Q
rs393548 IL12RB1 T/A chr19:18058744 0.27 Promoter -111
rs7544381 IL12RB2 C/T chr1:67546881 0.49 Intron -
rs17129749 IL12RB2 C/T chr1:67552339 0.30 Intron -
rs17129751 IL12RB2 G/A chr1:67552503 0.04 Intron -
rs2307147 IL12RB2 T/C chr1:67559874 0.24 Coding exon 26 D/D
rs17129778 IL12RB2 A/T chr1:67560279 0.12 Intron -
rs17129792 IL12RB2 G/A chr1:67565087 0.04 Coding exon 149 R/Q
rs1495963 IL12RB2 C/T chr1:67567907 0.32 Coding exon 238 S/S
rs2307149 IL12RB2 A/T chr1:67568038 0.06 Intron (boundary) -
rs17838054 IL12RB2 G/A chr1:67589869 0.00 Intron -
rs2307145 IL12RB2 G/C chr1:67606115 0.11 Coding exon 426 Q/H
rs2307153 IL12RB2 G/A chr1:67606231 0.004 Coding exon 465 G/D
rs6685568 IL12RB2 A/G chr1:67627885 0.45 Intron -
rs2270614 IL12RB2 A/G chr1:67628609 0.17 Intron -
rs2229546 IL12RB2 C/A chr1:67634108 0.46 Coding exon 779 P/P
rs17838066 IL12RB2 T/G chr1:67634194 0.00 Coding exon 808 L/R
*MAF observed in this study.
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(P = 0.38) was found. These two minor alleles are com-
mon in the population studied here, 11% and 24%, for
rs2243140 and rs429774, respectively (Table 2).
Another SNP in IL12A, rs2243138, was associated
with protection from SA (P = 0.004) and SAP (P =
0.004) (Table 4). The children homozygous for the rare
allele (TT), of which the prevalence is 21.8% in this
population, had significantly lower risk for developing
SA (RR = 0.69, 95% CI: 0.53-0.89) and SAP (RR = 0.66,
95% CI: 0.49-0.89). A similar trend of association was
seen with SMA, but was not statistically significant after
adjusting for multiple comparisons (Additional file 1).
Another SNP in IL12RB1, rs383483, was associated
with HDP (P = 0.003) (Table 4). Having an AG geno-
type, which is common (45.8%) in this population, was
significantly associated with susceptibility to HDP at
1.21 (95% CI: 1.07-1.36) times greater risk compared
with those with AA or TT genotypes. No association
between SNPs from IL12B and IL12RB2 and malaria-
related morbidity was identified.
Because the single SNP regression analysis demon-
strated that multiple sites within IL12A and IL12RB1
genes are significantly associated with protection from
severe malaria anaemia (Additional file 1), analysis of
LD in these two genes (Figure 1) was performed respec-
tively. The two hit SNPs of IL12A, rs2243140 and
rs2243138, were in high LD (D’ = 0.98), but SNPs of
IL12RB1, rs383483 and rs429774, were not (D’ = 0.47).
This suggests that the associations shown by SNPs
rs2243140 and rs2243138 of IL12A may be related
whereas the rs383483 and rs429774 of IL12RB1 are
independent.
Discussion
In this paper, significant associations between poly-
morphisms within genes encoding the IL12A and
IL12RB1 and protection against SMA are identified. The
data shows that a SNP located within the 7th intron
boundary of the IL12RB1 gene (rs429774) is associated
with protection against developing SMA. In particular,
children possessing two minor alleles (C) had an 82%
decreased risk of SMA compared to those with one or
two copies of the major allele (T); this remained signifi-
cant after correction for multiple testing. The decreased
risk for developing SMA is also associated with increas-
ing minor allele (C) copy number in a SNP located
within the downstream of the IL12A gene (rs2243140).
Another two SNPs in IL12A (rs22431348) and IL12RB1
(rs383483) were associated with reduced risk of SA and
SAP and with increased risk HDP, respectively. There is
no evidence to support any significant association
between IL12B genetic variants and SMA or the 3 other
clinical phenotypes tested in this study. This suggests
that common genetic variations within IL12B did not
influence the severity of malaria in this Kenyan popula-
tion, despite previous reported associations of IL12Bpro
(rs17860508) with cerebral malaria in Tanzanian and
Malian, but not Kenyan children [23,34], and of several
Table 3 Protective effect of polymorphisms in the genes of IL12A and its receptor, IL12RB1, against severe malaria
anaemia
Severe malaria anaemia episodes crude incidence/1000 person-months Adjusted risk ratio (95% CI)a
IL12 A-rs2243140b TT TC CC CC vs TT TC vs TT P
12.2 7.7 0 0.28 (0.10-0.79) 0.52 (0.31-0.89) .006
IL12RB1-rs429774c TT TC CC CC vs (TT+TC) P
12.2 11.2 2.8 0.18 (0.05-0.69) .00005
NOTE.
a Adjusted by sickle cell type and treatment with anti-malarial drugs.
b An additive genetic model used for IL12A-rs2243140, which treats the marker as a continuous variable and is extrapolated based on Poisson model.
c A dominant model used for the second marker, IL12RB1-rs429774.
Table 4 Protective effect of polymorphisms in the genes of IL12A and its receptor, IL12RB1, against severe anaemia,
severe anaemia with any parasitaemia and high-density parasitaemia
Crude incidence/1000 person-months Adjusted risk ratio (95% CI)a
IL12 A-rs2243138b AA AT TT TT vs (AA + AT) P
Severe anaemia episodes 38.3 41.3 30.3 0.69 (0.53-0.89) .004
Severe anemia with any parasitaemia episodes 32.8 35.8 24.5 0.66 (0.49-0.89) .004
IL12RB1-rs383483c AA AG GG AG vs (AA+GG) P
High-density parasitaemia episodes 155.2 172.8 146.8 1.21 (1.07-1.36) .003
NOTE.
a Adjusted by sickle cell type and treatment with anti-malarial drugs.
b A dominant model used for IL12 A-rs2243138.
c A heterozygous advantage model used for IL12RB1-rs383483.
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Figure 1 Pairwise linkage disequilibrium (LD) plots of IL12A (a) and IL12RB1 (b) polymorphisms. Data from all 913 participants are
included. If LOD ≥ 2, red denotes D primer (D’) = 1; shades of pink/red, 0 < D’ < 1. If LOD < 2, white indicates 0 < D’ < 1. The number in each
box = 100 × D’ value, except D’ = 1 (the box is empty). The plots were generated using Haploview software.
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other diseases with variation in IL12Bpro (rs17860508)
and IL12B 3’ UTR (rs3212227) [35]. A lack of signifi-
cance in IL12B in this study may be the result of lack of
power or small sample size; however, a recent study
conducted in western African population also showed
that there was no association between these two known
cis-regulatory element polymophisms in IL12B and
malaria parasitaemia [36].
This study was conducted in a large and clinically
well-characterized cohort of children using a tagSNP
method based on the following considerations. First,
although methods have been developed to predict the
functional impact of variants such as nonsynonymous
coding SNPs, which introduce amino acid changes in
their corresponding proteins [35], these SNPs represent
a small subset of all common variants. Second, several
genome wide association studies have indicated that var-
iations in non-coding regions rather than nonsynon-
ymous coding SNPs are likely to be causative to disease
susceptibility or resistance in most instances [37]. Regu-
lation of the protein products, rather than differences in
the structure or function of the protein may be most
important for disease risk [38]. Third, many SNPs show
correlated genotypes, or LD, suggesting that a subset of
all SNPs (known as tagSNPs) can be genotyped for dis-
ease association studies [39]. Lastly, several tagSNP
methods have been developed to select a subset of SNPs
that efficiently describes existing patterns of variation in
candidate gene regions for subsequent genotyping and
association analysis, without making assumption about
the potential functional impact of each SNP [40]. An
efficient set of tagSNPs to cover each candidate gene
region, rather than simply focusing on a few putatively
interesting SNPs have been selected, such that genotype
at untyped SNPs can be accurately inferred from geno-
type at a tagSNP [28].
Previous immunological studies have shown that IL12
exerts its biological function via binding to its receptors.
This study has identified associations of polymorphisms
not only in IL12 related gene, IL12A, but also in its
receptor, IL12RB1 with SMA and HDP with different
effects. Two SNPs in the IL12A (rs2243140 and
rs2243138) and one SNP in the IL12RB1 (rs429774)
were associated with protection against SMA or SA
whereas one SNP in the IL12RB1 (rs383483) was asso-
ciated with susceptibility to HDP. There are a number
of studies that examined the effect of IL12 on erythro-
poiesis and malarial anaemia in mouse models, in which
IL12 was found to be extremely effective in correcting
malarial anaemia [12-14]. The dramatic effect of IL12
treatment is mediated by enhancement of erythroid pro-
genitor expansion in bone marrow and by immune reg-
ulation of IFN-g, TNF-a and NO [16]. In humans, a
decrease in IL12 production is also clearly associated
with SMA [18-20]. Although it remains unknown how
the noncoding polymorphic SNPs in IL12A and
IL12RB1 identified in this study control or regulate the
expression of IL12 and its receptors, the results from
this study support the assertion that non-coding regions
rather than nonsynonymous coding SNPs potentially
have effects on disease outcomes [39]. The results from
this study also suggest that the effects of IL12A and
IL12RB1 on malaria disease outcomes most likely result
from the long evolutionary history of P falciparum para-
site within the human population.
The IL23 pathway may offer further insights on the
genetic results from this study since IL23 and IL12
share the IL12p40 subunit encoded by IL12B and IL23
also binds to the IL12 receptor subunit encoded by
IL12RB1. A recent study has shown that children with
malarial anaemia had increased circulating IL23 and
IL10 and decreased IL12 relative to healthy controls in
Kenyan children, suggesting that IL23 and IL12 are
counter-regulators in malaria anaemia [20]. The find-
ings from this study that polymorphisms (3 SNPs) in
IL12A and IL12RB1, but not in IL12B, have protective
effects on SMA and one SNP in IL12RB1 has an oppo-
site effect on HDP are interesting. It is possible that
the genetic effects on disease outcomes observed in
this study may occur at the phenotypic level of IL12
and IL23 systems, which may be influenced by the
interaction of genetic variants in IL12A, IL12RB1 and
IL12B. This hypothesis requires testing. Currently,
whether the polymorphisms in IL12A and IL12RB1
observed in this study influence the level and expres-
sion of IL12, IL12 receptor and IL23 in vitro in rela-
tion to severity of malaria anaemia have being
examined in Kenyan children.
This study included a large sample size and used long-
itudinal data for association analysis. However, it will be
important to replicate these findings in additional Afri-
can populations [41]. These efforts are complicated by
the patterns of disease seen in regions of differing
malaria transmission, but these studies are needed to
allow us to further understand the most important path-
ways in successfully controlling infection by the malaria
parasite and to assess the effects of racial differences,
transmission intensity, and other environmental factors
on the interaction of IL12 related gene and severe
malaria anaemia. In addition, studies are needed to
examine whether the polymorphisms observed in these
genes influence the level and expression of IL12, IL12
receptor and IL23 in vitro in other African populations
in relation to malarial anaemia.
Conclusions
This study has shown strong associations between poly-
morphisms in the genes of IL12A and IL12RB1 and
Zhang et al. Malaria Journal 2010, 9:87
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protection from SMA in Kenyan children, suggesting
that human genetic variants of IL12 related genes may
significantly contribute to the development of anaemia
in malaria patients.
Additional file 1: Summary of p-value of associations between
genotypes tested and malaria-associated morbidity.
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